Psychosocial and Medication Treatment for Anxiety in Alcoholism
Alcohol-Related Disorders, Anxiety Disorders
About this trial
This is an interventional treatment trial for Alcohol-Related Disorders focused on measuring Venlafaxine, Alcoholism, Anxiety Disorders, Alcohol-Use Disorders, Alcohol Abuse, Alcohol Dependence, Cognitive Behavioral Treatment
Eligibility Criteria
Inclusion Criteria: Participants must be English-speaking males or females Participants must be between 18 and 65 years old Meet criteria for DSM-IV diagnosis of alcohol abuse or dependence Meet criteria for Panic disorder, Social Phobia or Generalized Anxiety Disorder Physically able to attend sessions at the Counseling Center Able to read and write Able to complete the structured interview and self-report assessment packet Able to attend all treatment sessions and follow-up assessments Able to sign a witnessed informed consent form Participants express a desire to completely stop drinking alcohol or reduce alcohol consumption with the possible long-term goal of abstinence Exclusion Criteria: Meet DSM-IV diagnostic criteria for bipolar disorder, schizophrenia, bulimia/anorexia, or dementia Currently taking anti-craving agents (e.g. Naltrexone, methadone) Currently taking medication that has clinically significant interactions with venlafaxine Previous use of venlafaxine Currently taking other antidepressant medications Currently taking medication known to decrease anxiety or alcohol consumption (e.g. antabuse) Currently prescribed medications with known abuse potential (e.g., subjects on opioid agonist therapy) Currently prescribed medications as a sleep aid (e.g. Ambien) Currently taking herbal supplements that have been shown to interact with venlafaxine or affect anxiety symptoms Currently pregnant, breastfeeding, plans of becoming pregnant during the course of the study, or not using medically acceptable form of birth control (oral contraceptives, barrier [diaphragm or condom] with spermicide, intrauterine progesterone contraceptive system, levonorgestrel implant, medroxyprogesterone acetate contraceptive injection). Planning to relocate out-of-state within four months of protocol initiation History of psychotic symptoms within the past 30 days Experiencing severe symptoms of depression or have engaged in suicidal behaviors within the past 30 days Medical contraindications to the use of venlafaxine [severe renal disease, cirrhosis, uncontrolled blood pressure, recent cardiovascular problems (e.g., heart attack), and seizure disorders; currently taking a monoamine oxidase inhibitor, MAOI] Self-reported anxiety less than 15 on the Hamilton Rating Scale for Anxiety Participant is a member of the same household of another subject already participating in the study Participant is legally mandated (e.g., to avoid incarceration, monetary or other penalties, etc.) to participate in an alcohol treatment program Participant has a current or recent (past 30 days) DSM-IV diagnosis of other substance abuse or dependence, with the exception of nicotine, marijuana, and caffeine
Sites / Locations
- Boston Medical Center
- Center for Anxiety and Related Disorders
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm 4
Experimental
Active Comparator
Active Comparator
Placebo Comparator
Venlafaxine & CBT
Placebo & CBT
Venlafaxine & PMR
Placebo & PMR
CBT is Cognitive Behavioral Treatment which will be tailored to participants. Participants will be assigned to a 12-week treatment condition; all treatment conditions will begin with a 1-week placebo run-in, after which participants will begin a trial of venlafaxine. The treatments will conclude with a 2-week medication taper.
CBT is Cognitive Behavioral Treatment which will be tailored to participants.For patients with comorbid alcohol-use and anxiety disorders, CBT and pharmacotherapy will be contrasted with relaxation training and placebo medication; all treatment conditions will begin with a 1-week placebo run-in, after which participants will begin a trial of venlafaxine or placebo.
Progressive Muscle Relaxation Therapy (PMR) is a technique of alternately tensing and relaxing muscles groups in sequence throughout the body. . Participants will be assigned to a 12-week treatment condition; all treatment conditions will begin with a 1-week placebo run-in, after which participants will begin a trial. The treatments will conclude with a 2-week medication/placebo taper.
Progressive Muscle Relaxation Therapy (PMR) is a technique of alternately tensing and relaxing muscles groups in sequence throughout the body. . For patients with co-morbid alcohol-use and anxiety disorders, CBT and pharmacotherapy will be contrasted with relaxation training and placebo medication; all treatment conditions will begin with a 1-week placebo run-in, after which participants will begin a trial of venlafaxine or placebo.